Blood cancers

Can CAR T-cell therapy now move to 2nd line treatment in lymphoma?

CAR T-cell therapies are showing huge promise as the future standard of care in hard-to-treat patients with relapsed or refractory large B cell lymphoma (LBCL) – but not every product wins. Speaking at the 63rd ASH Annual Meeting and Exposition, Associate Professor Manali Kamdar presented the results of the phase 3 study of lisocabtagene maraleucel ...

Already a member?

Login to keep reading.

© 2022 the limbic